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The main aim of phase I trials is to evaluate the tolerability and pharmacology of a new compound. However, investigating the
potential for clinical benefit is also a key objective. Our phase I trial portfolio incorporates a range of new drugs, including molecular
targeted agents, sometimes given together with cytotoxic agents. We performed this analysis of response rate, progression-free (PFS)
and overall survival (OS) to assess the extent of clinical benefit rate (CBR: partial response (PR)þstable disease (SD)) derived from
current trials. We analysed 212 consecutive patients who were treated in 29 phase I studies, from January 2005 to June 2006. All
patients had progression of disease prior to study entry. The median age was 58 years (range: 18–86) with a male/female ratio of
2:1. A total of 148 patients (70%) were treated in ‘first in human trials’ involving biological agents (132 patients) or new cytotoxic
compounds (16 patients) alone, and 64 patients (30%) received chemotherapy-based regimens with or without biological agents.
After a median follow-up time of 34 weeks, the median PFS and OS were 11 and 43 weeks, respectively. The CBR was 53% (9% PR
and 44% SD) after the first tumour evaluation after two cycles (between weeks 6 and 8) and has been maintained at 36 and 26% at 3
and 6 months, respectively. Treatment related deaths occurred in 0.47% of our patients and treatment had to be withdrawn in 11.8%
of patients due to toxicity. A multivariate analysis (MVA) of 13 factors indicated that low albumin (o35gl
 1), lactate
dehydrogenase4upper normal limit and 42 sites of metastasis were independent negative prognostic factors for OS. A risk score
based on the MVA revealed that patients with a score of 2–3 had a significantly shorter OS compared to patients with a score of
0–1 (24.9 weeks, 95% CI 19.5–30.2 vs 74.1 weeks, 95% CI 53.2–96.2). This analysis shows that a significant number of patients who
develop disease progression while receiving standard therapy derived benefit from participation in phase I trials. Risk scoring based on
objective clinical parameters indicated that patients with a high score had a significantly shorter OS, and this may help in the process
of patient selection for phase I trial entry.
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Patients with advanced cancers most commonly face the dilemma
of having no available standard treatment option. A minority of
patients with good performance status (PS) and adequate organ
function are sometimes offered treatment within the context of a
phase I trial. Phase I trials are designed primarily to evaluate the
tolerability and toxicity profile of new therapies. The generally
accepted inclusion and exclusion criteria for these trials include
adequate organ function and reasonable PS in order to ensure
safety and avoid unnecessary toxicity. Another important entry
criterion is life expectancy predicted to be more than 3 months,
and this is notoriously difficult to predict. More accurate selection
criteria or even prognostic scores for patients who will potentially
benefit from a clinical phase I trial may therefore be helpful.
So far, there have been few studies exploring factors associated
with clinical outcome, toxicity and prognosis in this context.
Multivariate analyses (MVAs) have revealed that factors such as
poor PS, high lactate dehydrogenase (LDH), low albumin, and
certain chemotherapy regimens could be negative prognostic
factors for survival. However, one of the drawbacks of these
studies has been that most analyses have been performed over a
long period of time, some of them over 10 years. Moreover, most of
these studies focused on the ‘classical cytotoxic drug development
era’ and not on the newer generations of molecularly targeted or
biological agents (Yamamoto et al, 1999; Han et al, 2003; Penel
et al, 2008).
Biological agents target a certain molecular structure or pathway
relevant for cancer growth. Broadly speaking, the mechanism of
action usually results in a cytostatic rather than cytotoxic effect,
resulting in lower toxicity to normal tissue.
We performed this retrospective analysis in all patients who
took part in phase I trials at the Drug Development Unit, Royal
Marsden Hospital, over an 18-month period, from January 2005 to
June 2006. During this period, the majority of our trials involved
Received 9 November 2007; revised 19 December 2007; accepted 7
January 2008; published online 18 March 2008
*Correspondence: Professor S Kaye; E-mail: stan.kaye@icr.ac.uk and
Dr H-T Arkenau; E-mail: hendrik-tobias.arkenau@icr.ac.uk
2These authors contributed equally to this work.
British Journal of Cancer (2008) 98, 1029–1033
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sbiological agents. Clinical parameters, blood tests (biochemistry
and full blood count (FBC)), tumour type, toxicity and type of
treatment were included in our univariate and MVAs. The main
aim of this study was to analyse the clinical outcome for our large
patient population treated in phase I trials. Secondly, we were
interested in the impact of the type of phase I trial on clinical
outcome. Our third aim was to analyse factors that could guide us
in the development of an improved patient selection process for
phase I trials.
PATIENTS AND METHODS
Patient characteristics
We analysed the outcome of 212 consecutive patients who were
treated from January 2005 to June 2006 in 29 phase I trials at the
Drug Development Unit, Royal Marsden Hospital, Sutton, UK. All
patients had to have objective evidence of progressive disease prior
to trial entry. The median age was 58 years (range: 18–86) with a
male/female ratio of 2:1 (142 male and 70 female). Overall, the
patients had a median of two cycles of prior systemic therapy
(range 0–8). The Eastern Cooperative Oncology Group (ECOG) PS
was 0, 1 and 2 in 28, 66 and 6% of patients, respectively. A total of
33.5% of the patients had urological tumours, 15.6% had breast
and gynaecological tumours, 14.2% had lung, mesothelioma and
head and neck tumours, 12.3% had sarcoma, 12.3% had
gastrointestinal tumours, 6.1% had melanoma, and 6.1% others.
Of the patients with urological tumours, 37 of 54 had prostate
cancer previously untreated with chemotherapy. Sixty-four per
cent had p2 sites of metastasis and 36% had X2 sites of
metastasis (median 2, range: 0–8). The most common sites of
metastasis were lung (41%), bone (29%) and liver (27%). Baseline
biochemistry showed decreased albumin levels in 57% of the
patients (albumin o35gl
 1) and LDH levels were above the upper
normal limit (UNL: 4192IU) in 49%. The FBC showed
haemoglobin levels o12gdl
 1 in 41%, a white cell count (WCC)
410500mm
 3 in 11% and platelets 4400000mm
 3 in 24% of the
patients (Table 1).
Trial characteristics
During the 18-month study period, all 212 consecutive patients
were treated within one of 29 phase I trials. A total of 148 patients
(70%) were treated in ‘first in human trials’ involving biological
agents (132 patients) or new cytotoxic compounds (16 patients)
alone and 64 patients (30%) received chemotherapy-based regi-
mens with or without biological agents. According to the various
protocols, the first tumour evaluation was performed before the
third cycle, between weeks 6 and 8. Trial categories are
summarised in Table 1.
Of our 29 trials, 19 trials have already been completed and phase
II doses were recommended; 17 of the 19 trials reached maximum-
tolerated doses (MTDs). Three trials were closed early based on the
sponsor’s decision. Seven trials are still ongoing and four of them
have reached MTDs. Overall, MTDs were defined for 21 of the 29
trials.
Statistical consideration
The SPSS Programme (Version 12.0, Chicago, IL, USA) was used
for statistical analysis. The Kaplan–Meier method was used to
estimate progression-free (PFS) and overall survival (OS) and the
log-rank test was used to compare the survival curves (Kaplan and
Meier, 1958). The Cox regression model has been applied for HR
estimation and for MVA of prognostic factors for PFS and OS,
using a backward selection approach (Cox, 1972). Fisher’s exact
test and the w
2 test for trend were used to compare proportions of
Table 1 Baseline patient and treatment characteristics
Characteristics Median (range) Number %
Sex
Male 142 67
Female 70 33
Age 58 years (19–86)
o65 years 147 69
X65 years 65 31
Performance status 208
ECOG 0 58 28
ECOG 1 137 66
ECOG 2 13 6
Previous treatments 2( 0 – 8 )
0–2 previous systemic lines 110 52
X3 previous systemic lines 102 48
Number of involved areas 2( 0 – 8 )
Only locoregional disease 14 7
1–2 metastatic sites/areas 121 57
X3 metastatic sites/areas 77 36
Metastatic specific sites
Liver 57 27
Lung 86 41
Bone 62 29
Baseline albumin 33gl
 1 (18–44)
o35gl
 1 91 57
X35gl
 1 121 43
Baseline LDH level 190IUdl
 1 (55–2024)
Normal LDH 108 51
Elevated LDH 104 49
Baseline Haemoglobin level 11.95gdl
 1 (8.7–16.0)
o12gdl
 1 86 41
X12gdl
 1 126 59
Baseline WBC count 7150mm
 3 (2900–
21200)
p10500mm
 3 188 89
410500mm
 3 24 11
Baseline platelets count 284000mm
 3
(108000–797000)
p400000mm
 3 162 76
4400000mm
 3 50 24
Cancer group 208
Urological tumours 71 34
Breast and gynaecological cancers 33 16
Gastrointestinal cancers 26 12
Sarcomas 26 12
Thoracic and head and neck tumours 30 14
Melanoma 13 6
Others 13 6
Trial categories
‘First in human drugs’ 148 70
Cytotoxic drug combinations (including
FDA approved drugs)
64 30
Trial categories by target
Growth factor receptor pathways 63 30
Chromatin remodelling, DNA repair and
antisense
41 19
Anti-angiogenesis 38 18
Cell cycle and apoptosis 27 13
Vaccine and virus 16 7.5
New cytotoxic compounds 16 7.5
Hormone synthesis 8 4
Protein turnover 3 1
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sresponse rate (RR). All P-values presented are two-sided. The
cutoff date for the present analysis was the 31 May 2007.
Outcome: response, PFS and OS
Of the 212 patients, 202 (95%) had disease evaluable by the
acknowledged standard Response Evaluation Criteria in Solid
Tumours (RECIST) and Prostate Specific Antigen Working Group
criteria (PSAWG) were also used to determine progressive disease
but not response in this specific setting (Bubley et al, 1999;
Therasse et al, 2000). Overall, there has been a radiological proven
partial response (PR) in 19 patients (9.4%), stable disease (SD) in
88 patients (44%) and progression of disease in 95 patients (47%)
of all patients, respectively. The clinical benefit rate (CBR:
PRþSD) was 53% after the first tumour evaluation after two
cycles of treatment (between weeks 6 and 8) and has been
maintained at 36 and 26% at 3 and 6 months, respectively. Patients
who received a chemotherapy-based regimen had a RR of 19.7%
and patients who received a biological agent 3.6% (P¼0.01). The
median duration of treatment was 6.9 weeks (range: 0–60.1 weeks)
in patients who received a biological agent and 10.6 weeks (range:
0.1–64.4 weeks, P¼0.027) in patients who received a chemo-
therapy-based regimen with or without a biological agent. The 30- and
90-day mortality was 1.9% (4 out of 212) and 18.3% (39 out of 212),
respectively. Treatment related mortality was 0.47% (1 out of 212)
and 11.8% (25 out of 212) of the patients have been withdrawn
from an ongoing study due to toxicity (Table 2).
After a median follow-up of 34 weeks (range: 2.7–131.9), the
PFS was 11 weeks (95% CI: 9.9–11.8) and the median OS 43 weeks
(95% CI: 3.8–50.3), respectively (Figure 1). Univariate analysis
revealed that ECOG PS 2, 42 sites of metastasis, albumin
o35gday
 1, LDH4UNL, WCC 410500mm
 3, haemoglobin
o12gdl
 1, platelets 4400000mm
 3, among other factors, were
highly significant negative prognosticators for OS. In the MVA,
LDH4UNL (P¼0.003), albumin o35gdl
 1 (Po0.001), and 42
sites of metastasis (P¼0.01) were significant negative prognos-
ticators for OS (Table 3). Since our patient population included a
number of chemonaive prostate cancer patients and our trial
Table 2 Trial responses and outcomes
‘First in human’
Overall Median (range) – n/N (%) Chemotherapy-based P-value
Number of Cycles 2 (1–17) 2 (1–17) 4 (1–17) o0.001
Treatment (weeks) 7.7 6.9 10.6 0.027
Partial response 19/202 (9.4) 5/140 (3.6) 14/62 (22.6) 0.001
Stable disease 43 months 54/202 (26.7) 31/140 (22.1) 23/62 (37.1) o0.01
CBR3m (PR+SD43 months) 73/202 (36.1) 36/140 (25.7) 37/62 (59.7) 0.001
30 days mortality rate 4/212 (1.9) 2/148 (1.3) 2/64 (3.1) NS
90 days mortality rate 39/212 (18.3) 28/148 (18.9) 11/64 (17.2) NS
Toxicity-related mortality 1/212 (0.47) 1/148 (0.7) 0/64 (0) NS
Off-trial due to toxicity 25/212 (11.8) 19/148 (12.8) 6/64 (9.4) NS
CBR3m¼3 months clinical benefit rate; NS¼not significant; PR¼partial response; SD¼stable disease. P-values calculated by Mann–Withney’s U-test, w
2 test and Fisher’s F-test.
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Figure 1 Kaplan–Meier Curves for progression-free (PFS) and overall
survival (OS).
Table 3 Overall survival and prognostic factor categories (log-rank test
for univariate analysis and Cox regression for multivariate analysis)
Statistical analysis
(n¼212)
Median
(weeks) 95% CI
Univariate
Log Rank
Multivariate
Cox Reg
Albumin o35gl
 1 26 18.6–33.4 o0.0001 0.007
Normal albumin 74 54.3–95.1
Elevated LDH 34 24.3–44.0 0.003 0.002
Normal LDH 59 41.6–77.0
WCC 410500mm
 3 16 5.7–26.3 o0.0001 0.439
Normal WCC 47 36.6–56.8
HGB o12gdl
 1 31 22.4–39.0 0.0001 0.309
Normal HGB 60 37.9–82.4
PLT 4400000mm
 3 23 8.3–37.7 0.0035 0.394
Normal PLT 47 35.8–57.4
42 MTS sites 30 18.3–40.8 0.0007 0.025
0–2 MTS sites 52 38.1–65.0
Female 26 11.6–40.4 0.027 0.618
Male 54 39.7–67.5
o65 years 38 30.1–46.2 0.0271 0.343
X65 years 60 25.6–94.6
Liver MTS 25 22.7–27.0 0.0186 0.574
No liver MTS 47 36.8–56.6
Lung MTS 36 25.3–45.6 0.0234 0.0804
No Lung MTS 54 38.5–45.8
No Bone MTS 38 29.8–46.4 0.0004 0.425
Bone MTS 88 60.1–115
Non-urologic tumours 26 17.8–34.8 o0.0001 0.001
Urologic tumours 98 67.6–129
ECOG 0–1 44 34.8–54.3 0.0048 0.376
ECOG 2 17 12.6–22.8
Monotherapy trial 38 44.9–108 0.0005 0.157
Combination trial 76 28.4–47.8
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sportfolio included docetaxel regimens, we also assessed the
outcome according to disease type; urologic vs non-urologic
cancer. Urologic cancers were associated with a significant better
outcome compared to non-urologic cancers, P¼0.001 (Table 3).
A risk score based on the results of the outcome of the MVA
(LDH normal¼0 vs LDH4UNL¼1, albumin 435gl
 1¼0 vs
o35gl
 1¼1, site of metastasis o2¼0 vs 42¼1) demonstrated
that patients with a score o2 had a significantly longer OS (74.1 vs
24.9 weeks, P¼0.0001). Moreover, the same score remained highly
predictive for urological patients, a subgroup with a significant
better OS, and could also distinguish between a good and poor
prognosis cohort in this group of patients (Figure 2A, B and C).
DISCUSSION
The primary objectives of a phase I trial have classically been to
determine the toxicity profile of a new drug therapy and its MTD.
However, the clinical outcome measured in RR, PFS and OS is
usually descriptive due to the small numbers of patients enrolled in
these studies.
Previous retrospective analyses have studied the outcome for
patients on phase I trials and have reported RRs between 3.8 and
17.8% with higher RR in patients who received classical cytotoxic
drugs compared to patients who received biological agents (Sekine
et al, 2002; Roberts et al, 2004; Horstmann et al, 2005). These
studies however reviewed the outcome over a long period of time,
sometimes more than 10 years, which may not reflect the current
status of drug development. Moreover, these trials analysed only
the published outcome of clinical trials rather than individual
patient data.
In our patient group, with a broad spectrum of different cancers,
the RR was 9.4% and median PFS and OS were 11 and 43 weeks,
respectively, after a median follow-up of 34 weeks. Patients who
received a chemotherapy-based regimen with or without a
biological agent had significantly higher RR compared to patients
who received non-cytotoxic agents (19.7 vs 3.6%). These results are
in keeping with the aforementioned published analysis comprising
more than 460 phase I trials over a 12-year period, which found an
RR of 17.8% for patients who received a chemotherapy-based
regimen compared to 4.4% for patients who received non-
cytotoxic agents. No data were available on patients achieving
SD, nor was a survival analysis performed in that study
(Horstmann et al, 2005).
A patient-specific analysis was performed in a single centre
retrospective analysis, which enrolled 420 patients treated within
16 phase I trials over a 10-year period. This study showed OS rates
of 38 weeks for patients who received cytotoxic-based regimens
compared to 27 weeks for patients who received non-cytotoxic
treatment. These results were similar to our survival analysis,
which showed that classical cytotoxic-based regimens resulted in
longer OS compared to biological agents. This trial also confirmed
that RR was significantly higher in patients receiving cytotoxic
agents compared to patients who received non-cytotoxic agents
(14.1 vs 1%, Po0.001) (Han et al, 2003).
Our series demonstrated a better outcome for patients who had
disease control (CBR: PRþSD), which was reflected in an overall
CBR of 36% at 3 months and 26% at 6 months, respectively. It is
notoriously difficult to attribute a better outcome to treatment
effect in a non-randomised study analysis where patient selection
clearly is a major factor. However, the achievement of SD lasting
more than 3 months in advanced cancer patients with previous
disease progression is noteworthy, and in several cases has
justified the further development of the agent under investigation.
The patients who died within the first 3 months of treatment
reflected a group with an unfavourable prognosis. Our analysis
showed that these patients had significantly higher LDH, WCC and
lower albumin and haemoglobin levels compared to the rest of the
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Figure 2 OS by risk categories. Kaplan–Meier curves for OS based on
MVA risk score (albumin o35gl
 1, þ1; elevated LDH4UNL, þ1; 42
sites of metastasis, þ1). (A) Whole series (n¼212), score 0–1 (n¼119)
and score 2–3 (n¼93). (B) Non-urological cancers (n¼141), score 0–1
(n¼73) and score 2–3 (n¼68). (C) Urological tumours (n¼71), score
0–1 (n¼46) and score 2–3 (n¼25).
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spopulation. Similar results were demonstrated in a study, which
included 70 phase I patients. All patients who presented with the
following two risk factors, albumin o38gl
 1 and lymphocyte
count o0.7 10
9l
 1, died within 90 days (Penel et al, 2008).
Another study, which analysed 154 patients over an 8-year period,
identified two independent risk factors, namely LDH 4600IU and
PS 41, which were correlated with a shorter 90-day OS for patients
with both factors. The authors recommended that patients with
these risk factors should not participate in a phase I trial (Bachelot
et al, 2000). Interestingly, this study also revealed that patients
X65 years had a significantly better OS than younger patients in
keeping with our findings. A possible explanation includes more
aggressive tumour biology in younger patients.
In our MVA, parameters such as LDH4UNL, albumin
o35gl
 1, sites of metastasis 42 have been associated with a
significantly poorer clinical outcome. On the basis of these results,
a prognostic score model was developed (LDH normal (0) vs
LDH4UNL (þ1), albumin 435gl
 1 (0) vs albumin o35gl
 1
(þ1), site of metastasis o2 (0) vs 42( þ1)). Our prognostic
score demonstrated that patient with a good risk score (0 and 1
risk factors) had significantly superior OS compared to patients
with a poor risk score (42 risk factors). This score has been also
proved to be valid in the subgroup of urological cancer patients.
The use of this score might be helpful for the future as it is based
solely on objective clinical parameters. It could be a helpful tool in
evaluating the eligibility of patients into phase I trials. We are
currently performing a prospective analysis in our phase I patients
to validate this scoring system.
This analysis demonstrated that treatment within the context
of a phase I trial could be considered as a valuable therapeutic
option. Interestingly, those trials incorporating classical cytotoxics
were associated with a better outcome. Clearly, this relates
to patient selection, particularly when the trial may involve
the use of a cytotoxic in chemonaive cases. The treatment in
our cohort was generally well tolerated and treatment-related
deaths and toxicities were low. Moreover, a significant number of
patients achieved disease control for a significant duration.
However, the challenge remains in appropriate patient selection
and for this, the use of an objective clinical score could be a
helpful tool.
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